Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Colchicine for preventing stroke in patients with and without intracranial atherosclerotic stenosis: a prespecified analysis of a randomized clinical trial
First author：Jiejie Li,Jing Jing
Corresponding author：Yongjun Wang
essential_information
- Person in charge：Jiejie Li,Jing Jing
- Data Sources： CHANCE-3
- Number of papers：CHANCE-320250034
- Published time：2025-05-19
2025-05-19
Published articles
Journal：eClinicalMedicine
Publication type: Original Contributions
IF(IF): 10
PMID: 40496882 Link To Pubmed Full text Download
Background And Purpose
Limited therapies are available to patients with stroke due to ICAS, who are at particularly high risk of a recurrent stroke. In the recent CHANCE-3 trial, conducted 2022–2023, the effect of colchicine on rates of early recurrent stroke differed according to age (interaction p = 0.02), raising the hypothesis that patients younger than 65 years of age may benefitfrom colchicine.
Method
Cox proportional hazards regression was performed with treatment, presence of sICAS, and the treatment by presence of sICAS interaction as covariates, to test the interaction between the differential effects of colchicine versus placebo on efficacy and safety outcomes.